Reyon Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Reyon Pharmaceutical makes prescription medicines, including antibiotics, cardiovascular, digestive, and respiratory drugs, as well as a contrast agent used in CT scans and active pharmaceutical ingredients supplied to other drug makers.
Listed on KOSPI, Korea's main stock exchange, it serves hospitals, clinics, and pharmaceutical manufacturers. Its revenue is spread across three streams, prescription drugs, the CT contrast agent Optiray distributed under an exclusive domestic supply agreement with ISK (Imaging Solution Korea), and raw pharmaceutical ingredients such as tacrolimus and teicoplanin.
Summary is AI-generated and may contain errors · figures from DART filings
Reyon operates a dedicated biopharmaceutical manufacturing facility in Cheongju that has obtained Korean GMP certification for both chemical and biological medicines, and it pursues a contract manufacturing (CMO) business model alongside its own drug pipeline.
Reyon Pharmaceutical in five facts
What does Reyon Pharmaceutical do?
Reyon Pharmaceutical makes prescription medicines, including antibiotics, cardiovascular, digestive, and respiratory drugs, as well as a contrast agent used in CT scans and active pharmaceutical ingredients supplied to other drug makers.
Where is Reyon Pharmaceutical listed and in which sector?
Reyon Pharmaceutical (Korean name: 이연제약) trades under KRX code 102460 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Reyon Pharmaceutical?
Its market capitalisation was US$139.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Reyon Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Reyon Pharmaceutical reported revenue of US$110.1M, an operating loss of US$22.8M and a net loss of US$22.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 1.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 20
- DisclosureOct 16
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Oct 16
- [Amended] Material event report (convertible bonds)
Reyon Pharmaceutical updated the terms of convertible bonds to raise US$8.25M, about 5.9% of its market value.
Capital raise · Oct 13 - Material event report (convertible bonds)
Reyon Pharmaceutical disclosed convertible bonds to raise US$7.45M, about 5.4% of its market value.
Capital raise · Oct 8 - Material event report (convertible bonds)
Reyon Pharmaceutical disclosed convertible bonds to raise US$8.19M, about 5.9% of its market value.
Capital raise · Oct 8 - Report on large shareholdings (5% rule) (standard)Oct 8
- Change in shares held by the largest shareholderSep 28
- Report on large shareholdings (5% rule) (standard)Sep 28
- Material event report (decision to redeem own convertible bonds early)Capital raise · Sep 28
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Reyon Pharmaceutical reported consolidated results for FY2025: revenue of US$100M (−1.6% year on year), an operating loss of US$20.8M (from a profit a year earlier) and a net loss of US$20.4M (from a profit a year earlier).
Earnings · Feb 10